Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (FDA) for clobetasol propionate cream USP, 0.05%, the generic version of Temovate cream, 0.05%, of Fougera Pharmaceuticals, Inc.

According to IQVIA sales data for the 12 month period ending March 2018, the Temovate cream, 0.05% market achieved annual sales of approximately $118.0 million.

Glenmark’s current portfolio consists of 134 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.